Typo Corrections to the Company's 2021 Annual
Report
Date of events
2022/08/08
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event: 2022/08/08
2.Company name: Foresee Pharmaceuticals Co., Ltd.
3.Relationship to the Company (please enter "head
office" or "subsidiaries"): Head office
4.Reciprocal shareholding ratios: N/A
5.Cause of occurrence: Typo corrections to the Company's 2021 Annual Report
6.Information items/ statements to be corrected: 2021 Annual Report
7.Amounts/ contents/ number of page to be corrected:
(1) Page 81 of the Chinese-version 2021 Annual Report : 4. Competition of
Products : The annual sales of ELIGARD is approximately US$1,900
million in the US and Europe in 2018.
(2) Page 27 of the English-version 2021 Annual Report: (VI) Management
Team : Experience (Education) of Senior Vice President of CMC and
Manufacturing, Jagdish Parasrampuria, typo in the contents.
8.Amounts/ contents/ number of page after correction:
(1) Page 81 of the Chinese-version 2021 Annual Report : 4. Competition of
Products : The annual sales of ELIGARD in 2018 was approximately
US$190 million in the US and Europe.
(2) Page 27 of the English-version 2021 Annual Report: (VI) Management
Team : Experience (Education) of Senior Vice President of CMC and
Manufacturing, Jagdish Parasrampuria :
Ph.D. in Pharmaceutics of University of Houston, Texas Medical Center,
Houston
Scientific Director, Drug Product Development, Johnson & Johnson
Executive Director, Sunovion Pharmaceuticals
Vice President, Palatin Technologies
9.Countermeasures: To upload the Company's revised Chinese and English 2021
Annual Reports onto the MOPS.
10.Any other matters that need to be specified: None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Foresee Pharmaceuticals Co. Ltd. published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 August 2022 09:13:01 UTC.
Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.
FORESEE PHARMACEUTICALS CO., LTD. 
